[
  {
    "ts": null,
    "headline": "Dodge & Cox Stock Fund Q2 2025 Shareholder Letter",
    "summary": "Dodge & Cox Stock Fund stays focused amid market swings, boosting value with Health Care picks. Discover how disciplined investing drives results",
    "url": "https://finnhub.io/api/news?id=0a1cfacfa5e3eb86b51afeda1e7ee4129f0bd49dd711e8ade970bda0809035b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753220700,
      "headline": "Dodge & Cox Stock Fund Q2 2025 Shareholder Letter",
      "id": 136037246,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/874979248/image_874979248.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Dodge & Cox Stock Fund stays focused amid market swings, boosting value with Health Care picks. Discover how disciplined investing drives results",
      "url": "https://finnhub.io/api/news?id=0a1cfacfa5e3eb86b51afeda1e7ee4129f0bd49dd711e8ade970bda0809035b5"
    }
  },
  {
    "ts": null,
    "headline": "Albertsons Can Consistently Beat Its Identical Sales Growth Algorithm Through 2026, UBS Says in Upgrade",
    "summary": "Albertsons (ACI) has the potential to consistently beat its identical sales growth algorithm through",
    "url": "https://finnhub.io/api/news?id=116bbb550e6ccea35020e909e29b8b81d79ea054bac56a7cabf9b246c09dc06b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753212203,
      "headline": "Albertsons Can Consistently Beat Its Identical Sales Growth Algorithm Through 2026, UBS Says in Upgrade",
      "id": 136038442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Albertsons (ACI) has the potential to consistently beat its identical sales growth algorithm through",
      "url": "https://finnhub.io/api/news?id=116bbb550e6ccea35020e909e29b8b81d79ea054bac56a7cabf9b246c09dc06b"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks",
    "summary": "CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
    "url": "https://finnhub.io/api/news?id=e685a583cffec6c22a4c2f4047048068c9eaa0f103aa60fe41f447eb19fc3087",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753191302,
      "headline": "Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks",
      "id": 136033633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
      "url": "https://finnhub.io/api/news?id=e685a583cffec6c22a4c2f4047048068c9eaa0f103aa60fe41f447eb19fc3087"
    }
  },
  {
    "ts": null,
    "headline": "Walgreens sets sights on major clinical trial network growth",
    "summary": "The US pharmacy’s clinical trials business aims to address industry-wide challenges in trial recruitment and diversity.",
    "url": "https://finnhub.io/api/news?id=de6d41acbf3d023bdb218961aee14fdc09b4150167c18313dcd464395c2acb41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753190123,
      "headline": "Walgreens sets sights on major clinical trial network growth",
      "id": 136032384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The US pharmacy’s clinical trials business aims to address industry-wide challenges in trial recruitment and diversity.",
      "url": "https://finnhub.io/api/news?id=de6d41acbf3d023bdb218961aee14fdc09b4150167c18313dcd464395c2acb41"
    }
  },
  {
    "ts": null,
    "headline": "5 Low Price-to-Book Stocks That Should Be in Your Portfolio Now",
    "summary": "Low P/B stocks like CVS, SIG, KB, AMG and PAGS are flashing value signals with strong EPS growth projections and solid fundamentals.",
    "url": "https://finnhub.io/api/news?id=6401a930da5e50ed20463da3655f8a87e0d557970952109b832a796f13ffc240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753188900,
      "headline": "5 Low Price-to-Book Stocks That Should Be in Your Portfolio Now",
      "id": 136033635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Low P/B stocks like CVS, SIG, KB, AMG and PAGS are flashing value signals with strong EPS growth projections and solid fundamentals.",
      "url": "https://finnhub.io/api/news?id=6401a930da5e50ed20463da3655f8a87e0d557970952109b832a796f13ffc240"
    }
  },
  {
    "ts": null,
    "headline": "Oakmark U.S. Large Value Strategy Q2 2025 Commentary",
    "summary": "Oakmark U.S. Large Value Strategy's return was 4.48% (net) for the reporting period vs. Russell 1000 Value Index that returned 3.79% for the same period.",
    "url": "https://finnhub.io/api/news?id=ea6cd02417692e4b25e90b0ded4aa686f29368673279a84286c0ea3aa2e5fd6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753188660,
      "headline": "Oakmark U.S. Large Value Strategy Q2 2025 Commentary",
      "id": 136032888,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332441104/image_1332441104.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Oakmark U.S. Large Value Strategy's return was 4.48% (net) for the reporting period vs. Russell 1000 Value Index that returned 3.79% for the same period.",
      "url": "https://finnhub.io/api/news?id=ea6cd02417692e4b25e90b0ded4aa686f29368673279a84286c0ea3aa2e5fd6d"
    }
  },
  {
    "ts": null,
    "headline": "Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings",
    "summary": "EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.",
    "url": "https://finnhub.io/api/news?id=0c4bf280834120388fe0e3156f1505e9a363687072eea04c91e499c8a567f45a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753184580,
      "headline": "Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings",
      "id": 136031779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.",
      "url": "https://finnhub.io/api/news?id=0c4bf280834120388fe0e3156f1505e9a363687072eea04c91e499c8a567f45a"
    }
  },
  {
    "ts": null,
    "headline": "15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings",
    "summary": "Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.",
    "url": "https://finnhub.io/api/news?id=87d2d84e52c47bbd71b2829e008bb8e643e935610ca4a73cd7df2e711202c3f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753183212,
      "headline": "15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings",
      "id": 136031031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.",
      "url": "https://finnhub.io/api/news?id=87d2d84e52c47bbd71b2829e008bb8e643e935610ca4a73cd7df2e711202c3f6"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Has Become A Strong GARP Pick (Rating Upgrade)",
    "summary": "Current parameters surrounding CVS Health represent a biased reward/risk ratio. Click here to see why I upgraded my rating of CVS stock to Buy.",
    "url": "https://finnhub.io/api/news?id=ac375378fef7a1719c7c33521a3bd9cf84016559ca2bf35d481af3e582f99ac1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753160308,
      "headline": "CVS Health Has Become A Strong GARP Pick (Rating Upgrade)",
      "id": 136030172,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1142092741/image_1142092741.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Current parameters surrounding CVS Health represent a biased reward/risk ratio. Click here to see why I upgraded my rating of CVS stock to Buy.",
      "url": "https://finnhub.io/api/news?id=ac375378fef7a1719c7c33521a3bd9cf84016559ca2bf35d481af3e582f99ac1"
    }
  }
]